Plain-English translation of NCT04957329 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether the preservative-free version of latanoprost eye drops is gentler on your eye's surface than the more common preserved version. Both versions are used to treat glaucoma and high eye pressure, but researchers want to know if removing the preservative chemical makes a difference in how your eye tolerates the medication over time.
Eye drop preservatives can sometimes irritate the eye surface with long-term use, and this medication affects the protective mucus-producing cells in your eye. This study is trying to determine whether the preservative-free version causes less irritation and damage to these important cells.
You likely qualify if…
You likely don't qualify if…
You will use one type of eye drop in one eye and the other type in your other eye for 3 months—which eye gets which drop is decided randomly. Before you start and after the 3 months are complete, doctors will take a gentle print of the surface of your eye to measure how the drops affected your eye's protective cells. They will also check your eye pressure throughout the study.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Denmark
Phase
Post-approval monitoring
Sponsor
Rigshospitalet, Denmark
Collaborators
Laboratoires Thea
Enrollment target
~28 participants
Started
September 2021
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Anne Nagstrup, MD
Department of ophthalmology, rigshospitalet-Glostrup
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.